Our main drug candidate exhibits potent antiviral activity against Dengue and several other mosquito-borne viral infections.  It is currently undergoing lead optimization as TSG prepares to submit an Investigational New Drug application to the United States FDA. Based on current preclinical progress, we expect to obtain the US FDA “Qualified Infectious Disease Product” designation by late 2019. 

TSG’s antiviral technology is undergoing simultaneous development at some of the world’s most advanced research facilities — including the US Army Medical Research Institute of Infectious Diseases, National Institutes of Health and WHO Collaborating Centre for Research on Rabies Pathogenesis and Prevention — in order to develop solutions against a variety of other medically important viruses as well.